Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Outcomes in patients (pts) with baseline (BL) thrombocytopenia.

Authors

null

Claire N. Harrison

Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom

Claire N. Harrison , Miklos Egyed , Anita Szoke , Aleksandr Suvorov , Andrew Perkins , Jiri Mayer , Peter Ganly , Harry C. Schouten , Patrizia Tosi , Charles Michael Farber , Pierre Zachee , Christof Scheid , James P. Dean , Huafeng Zhou , Jean-Jacques Kiladjian , Alessandro M. Vannucchi , Jyoti Nangalia , Adam Mead , Ruben A. Mesa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders

Clinical Trial Registration Number

NCT01773187

Citation

J Clin Oncol 34, 2016 (suppl; abstr 7011)

DOI

10.1200/JCO.2016.34.15_suppl.7011

Abstract #

7011

Poster Bd #

3

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Annual Meeting

Efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia.

Efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia.

First Author: Pankit Vachhani

First Author: Prithviraj Bose

First Author: Haris Ali